Erowid
 
 
Plants - Drugs Mind - Spirit Freedom - Law Arts - Culture Library  
References Database

References Search
All References with Titles containing 'harm reduction' OR with Authors including 'harm reduction' OR with Abstract including 'harm reduction' OR with Keywords including 'harm reduction'


Author Title JournalName Year   D
Click on Column Headers to Re-Sort The Current List
Burroughs W Letter From A Master Addict To Dangerous Drugs British Journal of A... 1956
Dhawan BN Effect of drugs on LSD-25 induced pyrexia in rabbits. Arch.internat.de pha... 1959
Heninger GR, Bowers MB Adverse effects of niacin in emergent psychosis Journal American Med... 1968
Nichols DE Potential Psychotomimetics Bromomethoxyamphetamines And Structural Con... Diss.Abstr.Intern. B 1973
Andén NE, Corrodi H, Fuxe... Hallucinogenic Phenylethylamines: Interactions with Serotonin Turnover... Eur J Pharmacol 1974
Ananth J Congenital malformations with psychopharmacologic agents Comprehensive Psychi... 1975
MacDonald JF Pharmacology of dopamine receptors in the central nervous system of Pl... J.Physiol. 1976
Edvinsson L, Hardebo JE, ... Pharmacological Analysis of 5-Hydroxytryptamine Receptors in Isolated ... Circulation Res. 1978
Samanin R, Mennini T, Fer... m-Chlorophenylpiperazine: A Central Serotonin Agonist Causing Powerful... Naunyn-Schmiedeberg'... 1979
Editorial Arguments Heard for Psychedelics Probe Science 1980
McNall SJ, Mansour TE A Novel Serotonin Receptor In The Liver Fluke Fasciola Hepatica. Federation Proceedin... 1983
Vandermaelen CP, Aghajani... Electrophysiological and Pharmacological Characterization of Serotoner... Brain Research 1983
Mamounas LA, Molliver ME Evidence for dual serotonergic projections to neocortex: axons from th... Exp Neurol 1988
Jamieson DD, Duffield PH,... Comparison of the central nervous system activity of the aqueous and l... Arch Int Pharmacodyn... 1989
Nash JF, Nichols DE Microdialysis studies on 3,4-methylenedioxyamphetamine and structurall... Eur J Pharmacol 1991
Nichols DE, Johnson MP, O... 5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine Pharmacol Biochem Be... 1991
Lehmann J, DeSouza EB, Cu... Regional distribution to recovery of 5-HT levels after administration ... Ann N Y Acad Sci 1992
Hashimoto K Effects of benzylpiperazine derivatives on the acute effects of 3,4-me... Neurosci Lett 1993
Monte AP, Marona-Lewicka ... Synthesis and pharmacological examination of benzofuran, indan, and te... J Med Chem 1993
Chu T, Kumagai Y, DiStefa... Disposition of methylenedioxymethamphetamine and three metabolites in ... Biochem Pharmacol 1996
Finch E, Sell L, Arnold D Drug workers emphasise that water is not an antidote to drug BMJ 1996
Boys A, Lenton S, Norcros... Polydrug use at raves by a Western Australian sample Drug & Alcohol Revie... 1997
De Souza I, Kelly JP, Har... An appraisal of the pharmacological and toxicological effects of a sin... Pharmacol Toxicol 1997
Plessinger MA Prenatal exposure to amphetamines. Risks and adverse outcomes in pregn... Obstet Gynecol Clin ... 1998
Akram G, Galt M A profile of harm-reduction practices and co-use of illicit and licit ... Drugs: Education, Pr... 1999
Sexton TJ, McEvoy C, Neum... (+) 3,4-methylenedioxymethamphetamine ('ecstasy') transiently increase... Mol Psychiatry 1999
Vollenweider FX, Gamma A,... Is a single dose of MDMA harmless? Neuropsychopharmacol... 1999
Navarro JF, Maldonado E Behavioral profile of 3,4-methylenedioxy-methamphetamine (MDMA) in ago... Prog Neuropsychophar... 1999
Vollenweider FX, Remensbe... Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensor... Psychopharmacology (... 1999
Weir E Raves: a review of the culture, the drugs and the prevention of harm Canadian Medical Ass... 2000
Weinbroum AA, Rudick V, P... The role of dextromethorphan in pain control Can J Anaesth 2000
Winstock AR, Griffiths P,... Drugs and the dance music scene: a survey of current drug use patterns... Drug and Alcohol Dep... 2000
Shewan D, Dalgarno P, Rei... Perceived risk and risk reduction among ecstasy users; the role of dru... International Journa... 2000
Jasinski DR An evaluation of the abuse potential of madafinil using methylphenidat... J Psychopharmacology 2000
Varon J, Marik PE The diagnosis and management of hypertensive crises Chest 2000
Vastag B Ecstasy experts want realistic messages JAMA 2001
Chambers JJ, Kurrasch-Orb... Enantiospecific synthesis and pharmacological evaluation of a series o... J Med Chem 2001
Hansen D, Maycock B, Lowe... 'Weddings, parties, anything…', a qualitative analysis of ecstasy use ... International Journa... 2001
Winstock AR, Wolff K, Ram... Ecstasy pill testing: harm minimization gone too far? Addiction 2001
Baggott M Preventing problems in ecstasy users; Reduce use to reduce harm J Psychoactive Drugs 2002
Hayner, GN MDMA misrepresentation: An unresolved problem for ecstasy users J Psychoactive Drugs 2002
Bellis MA, Hughes K, Lowe... Healthy nightclubs and recreational substance use. From a harm minimis... Addict Behav 2002
Navarro JF, Maldonado E Acute and subchronic effects of MDMA ("ecstasy") on anxiety in male mi... Prog Neuropsychophar... 2002
Engelsman EL Cannabis Control: the model of the WHO tobacco control treaty International Journa... 2003
Gibbs T, Ross L Illicit drug use related attendances at accident and emergency service... Health Bull (Edinb) 2003
Mlinar B, Corradetti R Endogenous 5-HT, released by MDMA through serotonin transporter- and s... Eur J Neurosci 2003
Murray RA, Doering PL, Bo... Putting an Ecstasy test kit to the test: harm reduction or harm induct... Pharmacotherapy 2003
Cameron D Much, much more important than that Addiction Reasearch ... 2003
Tatarsky A Harm reduction psychotherapy: extending the reach of traditional subst... J Subst Abuse Treat 2003
Hasler F , Grimberg U, Be... Acute psychological and physiological effects of psilocybin in healthy... Psychopharmacology 2004
Macleod J, Oakes R, Copel... Psychological and social sequelae of cannabis and other illicit drug u... Lancet 2004
Khorana N, Pullagurla MR,... Pharmacological and neurochemical evidence for antidepressant-likeeffe... Pharmacology, Bioche... 2004
Schruers K, Griez E The effects of tianeptine or paroxetine on 35 CO2 provoked panic in pa... J Psychopharmacol 2004
Gamma A, Jerome L, Liecht... Is ecstasy perceived to be safe? A critical survey Drug and Alcohol Dep... 2005
Benveniste H, Fowler JS, ... Maternal and fetal 11C-cocaine uptake and kinetics measured in vivo by... J Nucl Med 2005
Segura M, Farre M, Pichin... Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetami... Clin Pharmacokinet 2005
Donovan JL, DeVane CL, Ma... Modafinil influences the pharmacokinetics of intravenous cocaine in he... Clin Pharmacokinet 2005
McCann UD, Szabo Z, Secki... Quantitative PET Studies of the Serotonin Transporter in MDMA Users an... Neuropsychopharmacol... 2005
Gresch PJ, Smith RL, Barr... Behavioral Tolerance to Lysergic Acid Diethylamide is Associated with ... Neuropsychopharmacol... 2005
Schifano F, Deluca P, Ago... New trends in the cyber and street market of recreational drugs? The c... J Psychopharmacol 2005
Schifano F, Deluca P, Ago... New trends in the cyber and street market of recreational drugs? The c... J Psychopharmacol 2005
Biederman J, Swanson JM, ... Efficacy and safety of modafinil film-coated tablets in children and a... Pediatrics 2005
Copeland J, Dillon P, Gas... Ecstasy and the concomitant use of pharmaceuticals Addict Behav 2006
Nordt C, Stohler R Incidence of heroin use in Zurich, Switzerland: a treatment case regis... Lancet 2006
Schifano F, Deluca P, Bal... Drugs on the web; the Psychonaut 2002 EU project Prog Neuropsychophar... 2006
Sheridan J, Butler R, Wil... Legal piperazine-containing party pills--a new trend in substance misu... Drug Alcohol Rev 2007
Allott K, Redman J Are there sex differences associated with the effects of ecstasy/3,4-m... Neurosci Biobehav Re... 2007
Jager G, de Win MM, Verva... Incidental use of ecstasy: no evidence for harmful effects on cognitiv... Psychopharmacology (... 2007
Vaglenova J, Pandiella N,... Aniracetam reversed learning and memory deficits following prenatal et... Neuropsychopharmacol... 2008
Tupper KW Teaching teachers to just say know: Reflections on drug education Teaching and Techer ... 2008
Tupper KW The globalization of ayahuasca: harm reduction or benefit maximization... Int J Drug Policy 2008
Smith Z, Moore K, Measham... MDMA powder, pills and crystal: the persistence of ecstasy and the pov... Drugs and Alcohol To... 2009
Bhide NS, Lipton JW, Cunn... Repeated exposure to MDMA provides neuroprotection against subsequent ... Brain Res 2009
Lucas P Moral regulation and the presumption of guilt in Health Canada's medic... Int J Drug Policy 2009
Karila L, Reynaud M GHB and synthetic cathinones: clinical effects and potential consequen... Drug Test Anal 2010
Sumnall HR, Evans-Brown M... Social, policy, and public health perspectives on new psychoactive sub... Drug Test Anal 2011
Van Hout MC, Bingham T 'A Costly Turn On': Patterns of use and perceived consequences of meph... Int J Drug Policy 2012
Winstock AR, Mitcheson L New recreational drugs and the primary care approach to patients who u... BMJ 2012
Kayser B, Broers B The Olympics and harm reduction? Harm Reduct J 2012
Absalom N, Eghorn LF, Vil... α4βδ GABAA receptors are high-affinity targets for ^... Proc Natl Acad Sci U... 2012
Moore K, Dargan PI, Wood ... Do novel psychoactive substances displace established club drugs, supp... Eur Addict Res 2013
Simojoki K, Alho H A Five-Year Follow-up of Buprenorphine Abuse Potential J Alcoholism Drug De... 2013
Kerr T, Small W, Hyshka E... 'It's more about the heroin': injection drug users' response to an ove... Addiction 2013
Dietze P Commentary on Kerr et al(2013): advertising high-potency heroin Addiction 2013
González D, Ventura M, Ca... Consumption of new psychoactive substances in a Spanish sample of rese... Hum Psychopharmacol 2013
Soussan C, Kjellgren A Harm reduction and knowledge exchange-a qualitative analysis of drug-r... Harm Reduct J 2014
Van Hout MC An Internet Study of User's Experiences of the Synthetic Cathinone 4-M... J Psychoactive Drugs 2014
Van Hout MC Nod and wave: an Internet study of the codeine intoxication phenomenon Int J Drug Policy 2015
Van Hout MC, Hearne E Word of mouse: indigenous harm reduction and online consumerism of the... J Psychoactive Drugs 2015
Gonzalez D, Torrens M, Fa... Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions BioMed Research Inte... 2015
D'Agnone O What have we learned and what can we do about NPS? Drugs and Alcohol To... 2015
Davis CS, Green TC, Zalle... Addressing the overdose epidemic requires timely access to data to gui... Drug Alcohol Rev 2015
Swogger MT, Hart E, Erowi... Experiences of Kratom Users: A Qualitative Analysis J Psychoactive Drugs 2015
Palamar JJ, Su MK, Hoffma... Characteristics of novel psychoactive substance exposures reported to ... Am J Drug Alcohol Ab... 2015
Racz J, Csak R, Toth KT, ... Veni, vidi, vici: The appearance and dominance of new psychoactive sub... Drug Alcohol Depend 2016
Palamar JJ, Salomone A, V... Detection of bath salts and other novel psychoactive substances in hai... Drug Alcohol Depend 2016
Brunt TM, Nagy C, Bücheli... Drug testing in Europe: monitoring results of the Trans European Drug ... Drug Test Anal 2016
Marshall BD, Green TC, Ye... Harm reduction for young people who use prescription opioids extra-med... Int J Drug Policy 2016
Csete J, Kamarulzaman A, ... Public health and international drug policy Lancet 2016
Vidal Giné C, Fernández C... Patterns of use, harm reduction strategies, and their relation to risk... Am J Drug Alcohol Ab... 2016

Page 1 of 2   /   138 Entries Returned
Pages:     
 1 
2 next